Mediastinal mass
Also known as: Mediastinum, Mediastinal, Septum, Septal
Methodology & AI Transparency ⓘ
Mediastinal mass Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Mediastinal mass uses ICD-10 R22.2 across Preventive & Labs specialty care.
- 3 Typical cash cost range: Primary evaluation for Mediastinal mass incorporates USPSTF age/sex-appropriate preventive in Mediastinal mass (R22.2: screenings) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Mediastinal mass: CBC, CMP & in Mediastinal mass (R22.2: eGFR Baseline) (Within optimal preventive reference intervals (R22.2)) and 25-Hydroxy Vitamin D, in Mediastinal mass (R22.2: Ferritin & B12).
Ask our AI Specialists anything about Mediastinal mass
What Is Mediastinal mass?
Recognized across U.S. clinical coding as R22.2 (Preventive & Labs), Mediastinal mass (also termed Mediastinum or Mediastinal) is evaluated via USPSTF age/sex-appropriate preventive in Mediastinal mass (R22.2: screenings) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in preventive & labs, Mediastinal mass (R22.2) involves preventive medical correction in Mediastinal mass (R22.2: during the reversible). progression correlates with shifts in CBC, CMP & in Mediastinal mass (R22.2: eGFR Baseline) (Within optimal preventive reference intervals (R22.2)).
Common Symptoms & Clinical Signs
- • Presentation of Mediastinal mass (R22.2): age- or family-history-guided in Mediastinal mass (R22.2: cancer, vascular, bone,)
- • Secondary Mediastinal mass clinical sign: proactive annual or in Mediastinal mass (R22.2: semiannual health checkup)
- • Symptom flares in Mediastinal mass correlating with CBC, CMP & in Mediastinal mass (R22.2: eGFR Baseline) deviation outside Within optimal preventive reference intervals (R22.2)
- • Functional preventive & labs impact requiring USPSTF age/sex-appropriate preventive in Mediastinal mass (R22.2: screenings) evaluation (R22.2)
Mediastinal mass Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R22.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NLM Clinical Tables |
| Diagnostic / Lab Marker: CBC, CMP & in Mediastinal mass (R22.2: eGFR Baseline) | Within optimal preventive reference intervals (R22.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Mediastinal mass (R22.2: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R22.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Mediastinal mass (R22.2: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R22.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mediastinal mass
Treatment selection for Mediastinal mass depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mediastinal mass)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Quality comparison of mediastinal lymph node dissection between video-assisted: What a 1,685-Participant Study Found This study found no significant differences in N2 upstaging proportions between the VATS and open. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2025-07-01 • Phase III Randomized Trial | N = 1,685 | 90/100 | PMID 40578313 ↗ |
| Can This Approach Help? Inside the Latest Research on Towards causal inference-based antidepressant selection with brain and blood While the accuracy of observed outcomes across treatment arms was 82%, the accuracies of predicted. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology • 2026-02-15 • Randomized Controlled Trial | N = 197 | 88/100 | PMID 40913094 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass On the basis of interim findings and the principle of nonmaleficence, the trial should be terminated. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40690727 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with In C5i-experienced patients, increased Hb levels correlated with improvement in FACIT-Fatigue scores (R = 0.48); in C5i-naive patients, increased Hb (R = 0.42) and decreased LDH (R = -0.53) (all P < .001) correlated with... Blood advances • 2025-04-22 • Phase III Randomized Trial | N = 40 | 82/100 | PMID 39774762 ↗ |
Mediastinal mass Patient Community & “People Like Me” Threads
Filter Mediastinal mass community threads and patient logs by age, biological sex, dosage, and treatment duration.